Source: Financial Times [UK]
“AstraZeneca, Daiichi Sankyo and Gilead have made big advances in treating the hardest-to-tackle type of breast cancer, boosting prospects for tens of thousands of patients a year. The drugmakers are unveiling trial results for existing blockbuster drugs in ‘triple negative’ breast cancer — so-called because it is not one of the three main types. These include the first ever study showing a medicine can extend the life of patients who cannot be treated with immunotherapy drugs, the majority of triple negative cases.” (10/19/25)